Finger regeneration whypeoplegetsick.com. An amazing testimony on how one man grew a new finger back simply by activating his own body's stem cells. Stem cell miracles are real - find out more how you can turn on and activate your own body's adult stem cells to bring back your health and even reverse the aging process. By: Jessica See … Continue reading →

Biology Group 7PM Region 1 minute short on Parkinson's Disease and how stem cell therapy could be a valid treatment for this disease plaguing the world. Group 7 PM: Tomas Okal, Long Dinh, McKinney Pierce, Blake Blackmon, and Matt Tateman By: tomasokal … Continue reading →

Now available on Research and Markets: This report analyses the future role stem cells will play in the pharmaceutical industry. The report will also deliver a complete understanding of the stem cell landscape through analysis of the developments that are taking place today and the companies who are going to impact the industry in the future. Dublin, Ireland (PRWEB) February 26, 2013 Stem cell technology is set to play a significant role in the pharmaceutical industry of the future. The opportunities for using stem cells across drug discovery, disease research, drug development and treatments are wide-ranging, yet largely unproven at present. Even if companies are not interested in joining the first wave of stem cell therapy developers, they need to be monitoring this sector in order to understand future competitive threats. The impact on drug discovery & development will impact the whole industry through a range of changes, from greater understanding of diseases to improved screening of drug candidates. With R&D pipelines across the industry still under pressure, collaboration between academia, stem cell specialist companies, pharmaceutical companies and government & regulators is needed to ensure the smooth and rapid advancement of these technologies. The report, Emerging Pharmaceutical Technologies - Stem … Continue reading →

WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC: NNVC) (the "Company"), announced that the renovation of the facility for its new clinical scale cGMP production plant has begun. The Company reports today that its project for enabling clinical scale drug product cGMP capability has reached a new milestone with the commencement of renovation of the facility at 1 Controls Drive in Shelton, CT. The design of this facility allows a very high degree of customization of the production process. This facility is thus expected to enable cGMP production of all of the Companys several nanoviricide drug candidates, in various delivery forms ranging from injectables, oral, eye drops, to skin creams. The Company has previously reported that it has approximately $20M cash in hand (including prepaid expenses) after the recent $6M raise. This raise involved only three family offices and a charitable foundation, all of who have been long term investors in and supporters of the Company. In addition, the Company has developed an innovative strategy to minimize its capital costs burden in the construction of its clinical drug product scale cGMP production facility, as previously described. The Company is moving forward on all of its initiatives at a steady pace. NanoViricides … Continue reading →

BOULDER, Colo.--(BUSINESS WIRE)-- Actium BioSystems disclosed today that its novel system platform, ACT, for selectively delivering controlled hyperthermia as an adjuvant to chemotherapy, has been validated via in vivo studies by two independent authorities, including Duke University Medical Center and a contract research facility. Actium is now preparing for safety and pharmacokinetic studies to support an application to the FDA for permission to commence First-In-Human clinical studies as soon as possible. The in vivo studies successfully demonstrated that Actium technology is able to selectively achieve therapeutic temperatures in the bladder using an intravesical (in the bladder) nanoparticle-mediated hyperthermia approach. It has been known for many years that heat weakens and kills cancer. But heat also affects normal, healthy tissue the same as cancer cellsexcept that low-temperature heat, from the normal body temperature of 370C (98.60F) to less than about 420C, has little effect on healthy tissue, but can weaken and kill cancer cells. This is the basic concept of treating cancer with low-temperature heat, called hyperthermia. The scientific literature on the efficacy of hyperthermia treatment is voluminous; numerous clinical studies have demonstrated hyperthermia can more than triple the efficacy of radiation therapy in select tumors without an increase in systemic … Continue reading →